 |
Postdoctoral Position in Molecular Cancer Genetics
Department of Health and Human Services
National Institutes of Health
National Human Genome Research Institute
The Reproductive Cancer Genetics Section, Cancer Genetics Branch of the National Human Genome Research Institute is seeking an outstanding Postdoctoral Fellow to investigate the molecular and genetic alterations underlying tumors originating within the human reproductive system. Our goal is to apply this knowledge to improve the diagnosis and treatment of cancer patients. Please refer to selected manuscripts by Bell DW in Science 1, New England Journal of Medicine 2, PNAS 3 and Nature Genetics 4. Successful candidates will lead projects that incorporate sophisticated technologies including array-based genomic and expression profiling, in combination with more traditional approaches to characterize DNA, RNA and proteins. Access to extensive core facilities including the NIH Intramural Sequencing Center, a genomics core facility, bioinformatics core, and transgenic mouse core, offers the trainee wide latitude in the design and pursuit of their research questions. Salary will be commensurate with research experience and is highly competitive. The Intramural Research program is located on the Bethesda campus and offers a wide array of training opportunities for scientists early in their careers. The Washington D.C. area also provides innumerable opportunities for cultural enrichment.
Candidates must have an M.D. and/or Ph.D. degree awarded within the past 3 years, a record of peer-reviewed publications, a solid command of English with the ability to speak and write effectively, and must be self-motivated to work independently.
Applications for this position are ongoing with a rolling deadline. To apply, go to NIH Research and Training Opportunities or send by mail or e-mail a CV, cover letter, a brief statement of research interests, and the names and telephone numbers of three references to:
Daphne W. Bell, Ph.D.
NHGRI/NIH
50 South Drive
Building 50, Room 5339
Bethesda, MD 20892-8002
E-mail: belldaph@mail.nih.gov
Daphne Bell's Web Page
The NIH and DHHS are equal opportunity employers.
The NIH is dedicated to building a diverse community in its training and employment programs.
Manuscripts
1 Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, and Haber DA. Heterozygous germline hCHK2 mutations in Li-Fraumeni Syndrome. Science, 286:2528-2531. 1999. [PubMed]
2 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350:2129-2139. 2004. [PubMed]
3 Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, and Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA, 102:7665-7670. 2005. [PubMed]
4 Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, and Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet, 37:1315-1316. 2005. [PubMed]
Top of page
Last Updated: September 28, 2009
|
|
|
|
